Tryptamine's TRP-8803 advances to Phase 2 trials, offering faster onset and safer control over psychedelic treatments via IV infusion. Phase 1b results highlight TRP-8803's precise dosing, safety ...

Tryptamine Therapeutics (AU:TYP) has released an update. Tryptamine Therapeutics Limited is offering 10,000 shares at $0.02 each, aiming to remove trading restrictions on shares issued before the ...

Tryptamine Therapeutics (AU:TYP) has released an update. Tryptamine Therapeutics, a biotech company listed on ASX, announced the results of its 2024 Annual General Meeting, where all resolutions ...

Tryptamine receives firm commitments to raise $6m in placement strongly supported by new and existing stakeholders Placement cornerstoned by Merchant Biotech Fund and biotech investor Dr Daniel ...